Kevin Tang buys $891k of Fulcrum Therapeutics stock

Kevin Tang buys $891k of Fulcrum Therapeutics stock

Tesla driver accelerated into house in fatal Texas crash, NTSB says Kevin Tang, a 10% owner of Fulcrum Therapeutics, Inc. (NASDAQ:FULC), and Tang Capital Management LLC, acquired a total of 249,946 shares of the company’s common stock across several transactions between July 13 and July 15, 2026. The total value of these purchases amounted to approximately $891,067, with prices ranging from $3.54 to $3.58 per share. The insider buying comes as the stock trades near its 52-week low of $2.83, down roughly 66% over the past six months.

According to InvestingPro analysis, FULC appears undervalued at current levels, with the stock trading below its Fair Value—making it one of the most undervalued stocks in the biotech sector. The transactions were conducted indirectly through various entities. Kevin Tang is the sole manager of Tang Capital Management, LLC, which serves as the general partner for Tang Capital Partners, LP ("TCP") and Tang Capital Partners International, LP ("TCPI").

He is also the sole director and Chief Executive Officer of Tang Capital Partners III, Inc. ("TCP III") and Tang Capital Partners IV, Inc. ("TCP IV"), which are indirectly wholly owned by TCP. Mr. Tang holds a pecuniary interest in the shares beneficially held by these entities. On July 13, 2026, 12,966 shares were purchased at a weighted-average price of $3.54 per share.

These shares were acquired in multiple transactions at prices ranging from $3.54 to $3.55. On July 14, 2026, two separate purchases were made. The first involved 53,651 shares at a weighted-average price of $3.56 per share, with individual transaction prices ranging from $3.54 to $3.60.

Later that day, an additional 75,952 shares were bought at a weighted-average price of $3.58 per share, with prices for individual transactions ranging from $3.53 to $3.60. The final reported transaction occurred on July 15, 2026, with the purchase of 107,377 shares at a weighted-average price of $3.56 per share. These shares were acquired in transactions priced between $3.50 and $3.60.

An InvestingPro tip notes that the RSI suggests FULC is in oversold territory, while 4 analysts have recently revised their earnings upwards for the upcoming period. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for FULC and 1,400+ other US equities, which transforms complex data into actionable intelligence. Following these acquisitions, the reporting persons indirectly hold a total of 6,913,329 shares of Fulcrum Therapeutics common stock.

In other recent news, Fulcrum Therapeutics has decided to discontinue its clinical program for pociredir in sickle cell disease. This decision follows feedback from the Food and Drug Administration (FDA), which raised concerns about the risk/benefit profile of the drug and potential secondary hematologic malignancies associated with its mechanism. As a result of this development, several investment firms have adjusted their ratings for Fulcrum Therapeutics.

Leerink downgraded the company’s stock to Market Perform, setting a price target of $4.00. H.C. Wainwright also downgraded the stock to Neutral from Buy, significantly reducing its price target to $3.00 from $25.00. Truist Securities followed suit, downgrading the stock to Hold and lowering its price target to $4.00 from $17.00.

Piper Sandler downgraded Fulcrum to Underweight from Overweight, adjusting its price target to $3.00 from $23.00. Additionally, Goldman Sachs has suspended coverage of Fulcrum Therapeutics, citing insufficient information to maintain an investment rating or provide earnings estimates. This article was generated with the support of AI and reviewed by an editor.

For more information see our T&C.